Skip to content

Lantheus Holdings LNTH Finished goods

Finished goods at other companies

Revvity logo
RevvityRVTY
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Danaher logo
DanaherDHR
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$377.3M+1.2%
Gross profit$230.9M-2.9%
Operating income$81.3M-20.3%
Net income$118.4M+62.3%
EPS (diluted)$1.80+76.5%

Balance sheet

See full
Cash & equivalents$500.3M-46.8%
Total debt$627.9M+1.8%
Total equity$1.2B+4.1%
Total assets$2.3B+14.2%

Cash flow

See full
Operating cash flow$125.1M+16.3%
CapEx$3.2M-63.0%
Free cash flow$121.9M+23.3%

Valuation

See full
Market cap$6.76B-26.3%
Enterprise value$6.89B-20.5%
P/E24.2×-10.2×
P/S4.4×-1.6×

Profitability

See full
Gross margin60.5%-3.6pp
Operating margin18.8%-10.7pp
Net margin18%+0.7pp
FCF margin24.4%-6.4pp

Returns & leverage

See full
Return on equity23.5%-1.7pp
Debt / equity0.5×0.0×
Current ratio2.8×-2.9×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: Lantheus Holdings’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lantheus Holdings's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lantheus Holdings's finished goods?
Lantheus Holdings (LNTH) reported finished goods of $22.31M in Q1 2026.
How has Lantheus Holdings's finished goods changed year-over-year?
Lantheus Holdings's finished goods decreased by 20.2% year-over-year, from $27.94M to $22.31M.
What is the long-term trend for Lantheus Holdings's finished goods?
Over 5 years (2020 to 2025), Lantheus Holdings's finished goods has grown at a 21.3% compound annual growth rate (CAGR), from $8.53M to $22.41M.